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Abstract  
Background Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver 
disease. At present there is no appropriate histologic scoring system available for 
PSC, evaluating both degree of necroinflammatory activity (grade) and fibrosis 
(stage). Aim of this study was to assess if three scoring systems, commonly used in 
different liver diseases could be applied for grading and/or staging of PSC. 
Methods Sixty-four PSC patients from a Dutch cohort, who underwent diagnostic 
liver biopsy, were included. Staging was scored using Ishak, Nakanuma, and Ludwig 
systems. Grading was scored using Ishak and Nakanuma systems. Three measures 
of outcome were defined; transplant-free survival, time to liver transplantation (LTx) 
and occurrence of cirrhosis related symptoms (CRS). Association of grade and stage 
with outcome was estimated using Kaplan Meier-log-rank test, and Cox regression 
analysis. Correlation with biochemistry was assessed by Spearman’s rank test.  
Results There were strong associations between disease stage measured by Ishak, 
Nakanuma and Ludwig staging systems with both outcome measure transplant-free 
survival (Hazard ratio (HR)2.56; 95%CI 1.11-5.89, HR6.53; 95%CI 2.01-21.22, 
HR1.94; 95%CI 1.00-3.79, respectively), and time to LTx (HR4.18; 95%CI 1.51-
11.56, HR7.05; 95%CI 1.77-28.11, HR3.13; 95%CI 1.42-6.87, respectively). Ishak 
and Nakanuma grading systems were not associated with CRS. Weak correlations 
between histopathology and liver biochemistry were shown.  
Conclusion Applying the Nakanuma, Ishak, and Ludwig histopathological staging 
systems is feasible and clinically relevant given their association with transplant-free 
survival and time to LTx. This suggests these staging systems may be likely 
candidates for surrogate endpoints and stratification purposes in clinical trials in PSC.  
Word count: 249 
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INTRODUCTION 
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease, 
characterized by progressive bile duct scarring and destruction, leading to biliary 
fibrosis and eventually progression to end-stage liver cirrhosis.[1] PSC diagnosis is 
established by means of cholangiography, performed by magnetic resonance 
cholangiopancreatography (MRCP) which is implemented as “golden standard”, and 
has replaced the more invasive endoscopic retrograde cholangiopancreatography 
(ERCP).[2,3] In case of large duct PSC, cholangiogram typically shows biliary 
strictures interchanged with dilatations creating the “beaded” appearance, and 
routine liver biopsy is not necessary to confirm diagnosis.[4] However, more subtle 
caliber changes can easily be missed on MRCP, and conversely, due to the 
moderate resolution of MRCP, false-positive findings may occur. In case of doubt, 
suspicion of small duct PSC, or auto-immune hepatitis (AIH) overlap syndrome, liver 
biopsy is indicated and essential to confirm diagnosis.[5,6] Furthermore liver biopsies 
have been used for the evaluation of treatment efficacy in therapeutic trials.[7–13]  
Histologic changes seen in PSC include the characteristic periductal 
concentric fibrosis leading to bile duct obliteration, infiltration of inflammatory cells in 
portal tracts, loss of bile ducts, bile ductular reaction and focal accumulation of 
copper binding protein (CBP).[1,14,15] Using liver histology, disease severity and 
progression can be assessed in terms of grade and stage.[16] Grade is usually used 
to describe the degree of necroinflammatory activity as measurement of the severity 
of the underlying disease process, while stage generally reflects the degree of 
fibrosis and cirrhosis as measurement of disease progression.[16]  
If a PSC appropriate histologic scoring system would have prognostic 
significance in terms of predicting the occurrence of solid clinical endpoints, liver 
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histology may be an important candidate for the evaluation of treatment efficacy in 
therapeutic trials. Evaluation of treatment efficacy by solid clinical endpoints such as 
death or liver transplantation (LTx), is hindered by the chronic disease course and the 
low prevalence of PSC.[18] Therefore, surrogate endpoints, including clinical 
biomarkers, biochemical biomarkers, Mayo risk score, and liver histology have often 
been used, but never been validated.[7–13] Currently, the lack of properly validated 
surrogate endpoints for clinical trials is one of the major challenges in PSC research. 
An important asset of liver histology is its face-validity, meaning that liver biopsy 
directly measures the degree of disease severity in the affected organ. However, it is 
currently unknown if face-validity is maintained in PSC livers where the patchy 
distribution may give rise to confounding sampling variability.[19]  
At present there is no specific PSC histologic scoring system with clinical 
significance, to evaluate both disease grade and stage. Commonly, the Ludwig and 
Ishak systems have been used to grade and stage histologic disease severity in 
PSC.[17,20] A drawback of the Ludwig staging system is that it was designed 
primarily to assess disease progression of primary biliary cirrhosis (PBC).[17] 
Furthermore, the Ludwig system does not separately score disease grade, and 
instead incorporates features such as portal and periportal inflammation, which are 
probably better regarded as manifestation of disease grade rather than stage.  
 Recently, Nakanuma et al, have proposed a new grading and staging system 
for primary biliary cirrhosis (PBC), which takes into account particular features that 
are shared with PSC, such as the presence of copper binding protein and loss of bile 
ducts.[21]  
The aim of this study was to determine the prognostic value of three different 
scoring systems, designed primarily to assess disease grade and/or stage in chronic 
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hepatitis (Ishak et al.) or PBC (Ludwig et al., Nakanuma et al.), for grading and/or 
staging of PSC.[17,20–22]  
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PATIENTS AND METHODS 
 
 Study design 
This cohort study is part of the ‘Epi PSC PBC project’, a large population-based 
cohort study of PSC and PBC in the Netherlands. All PSC patients alive on January 
1st 2000 and living in a geographically defined area of 6 adjacent provinces 
comprising 50% of the Dutch population were included in this study between January 
1st 2008 and December 31st 2011. The case-finding and case-ascertainment 
methods have been described previously.[18] The protocol was approved by the 
central Committee for Research Ethics in Utrecht and all 44 local ethics committees 
of the participating hospitals in the Netherlands (trialregister.nl number, NTR2813).   
PSC diagnosis was based on: 1) elevated alkaline phosphatase and gamma-
glutamyltransferase, not explained otherwise, 2) presence of characteristic bile duct 
changes with multifocal strictures and segmental dilatations on ERC or magnetic 
resonance cholangiography (MRC) and/or 3) liver histology and 4) no evidence for 
secondary sclerosing cholangitis. When criteria 1, 3 and 4 were fulfilled in the 
absence of cholangiographic abnormalities on MRC or ERC, cases were diagnosed 
as small duct PSC.[6] Autoimmune hepatitis (AIH) overlap syndrome (PSC- AIH) is ill 
defined. A diagnosis of PSC-AIH was made in patients with a characteristic 
cholangiogram who, in addition, met the simplified AIH criteria.[23]  
PSC patients from the Epi PSC PBC cohort, who underwent diagnostic liver 
biopsy or liver biopsy to assess disease severity at time of diagnosis between 1978 
and 2011, were included. Patients with PSC-AIH overlap syndrome were excluded. 
Biochemical values of aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), alkaline phosphatase (ALP), gamma-glutamyl transferase (γGT) and total 
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bilirubin at time of liver biopsy (range two months before until one month after liver 
biopsy) were retrieved from hospital databases and Mayo risk score was calculated. 
Clinical data reflecting liver cirrhosis related symptoms (CRS) at follow up were 
collected from patient files. CRS included gastro-esophageal varices and variceal 
bleeding, both assessed by gastrointestinal endoscopy, ascites, and splenomegaly 
assessed clinically and/or by imaging, and hepatic encephalopathy.  
 
Tissue preparation and histologic evaluation  
Original liver specimens, fixed in formalin and embedded in paraffin, as well as 
original liver stained sections were collected from the pathology department 
diagnostic archives. From each paraffin block thin sections were cut for haematoxylin 
and eosin (HE), connective tissue (Sirius red) and orcein stainings. Orcein staining 
was used to assess degree of copper binding protein (CBP) deposition in 
hepatocytes. If well preserved and available, original stained sections were used for 
histologic evaluation of biopsies. Otherwise, new stains were carried out. Grade and 
stage of biopsy specimens were evaluated using the three systems referred to above 
by two expert liver pathologists (JV & SH) in tandem using a multihead microscope, 
with the intention to reach consensus.  
Grading 
Grading was scored according to the Ishak system, evaluating degree of interface 
hepatitis (score 0-4), confluent necrosis (score 0-6), lobular inflammation (score 0-4) 
and portal inflammation (score 0-4).[20] Furthermore slides were scored according to 
the Nakanuma system, encompassing degree of cholangitis activity (CA) (score 0-3) 
and hepatitis activity (HA)(score 0-3).[21] (Supplementary appendix, table 1.) 
Staging 
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Staging was performed according the Ishak, as well as the Nakanuma and Ludwig 
systems.[17,20,21] With Ishak staging system degree of fibrosis is evaluated (0-6). 
The Nakanuma staging system is based on semi-quantitative scoring of three 
histological features - fibrosis (score 0-3), bile duct loss (score 0-3) and deposition of 
orcein positive granules (score 0-3). The final Nakanuma stage is obtained from the 
total score of these three features. Stage I (no or minimal progression) is a score of 
0, stage II (mild progression) a score of 1-3, stage III (moderate progression) a score 
of 4-6 and stage IV (advanced progression) a score of 7-9.[24] Ludwig staging 
system consists of 4 stages; stage I, cholangitis or portal hepatitis; stage II, periportal 
fibrosis or hepatitis; stage III, septal fibrosis, bridging necrosis or both; and stage IV, 
biliary cirrhosis. (Supplementary appendix, table 2.)  
 
Endpoints 
For analyses of association with endpoints, three different endpoints were chosen. 
The first endpoint was transplant-free survival, defined as time to PSC-related death 
(death from end-stage liver disease, liver surgery, cholangiocarcinoma and colorectal 
carcinoma), LTx and presentation with cholangiocarcinoma. Since the occurrence of 
cholangiocarcinoma may not be predictable by liver histology at time of diagnosis, 
second endpoint was time to LTx alone. The third endpoint was the occurrence of 
liver cirrhosis related symptoms (CRS) at follow-up. 
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Statistical Analysis 
Patient characteristics were expressed as mean ± standard deviation and median 
and interquartile range where appropriate.  
Association of histologic grade and stage with transplant-free survival, time to 
LTx and development of CRS was estimated using Kaplan Meier survival curve and 
Wilcoxon log-rank test. Due to relatively small sample size, and the resulting small 
amount of patients per grade and stage, survival analyses were performed in 
grouped subcategories. In this reclassification the order of severity of grade/stage 
was maintained; those subgroups with very few or no patients were grouped together 
with the grade/stage of most similar severity. Ishak grading components interface 
hepatitis, lobular inflammation and portal inflammation were reclassified in score 0, 1, 
≥2 (original score: 0-4), component confluent necrosis was reclassified in 0, ≥1 
(original score: 0-6), and the total Ishak grade was reclassified in score 1-4 (original 
score: 0-1 = 1; 2,3 = 2; 4 = 3; ≥5 = 4). Nakanuma grading component cholangitis 
activity was reclassified in 0, 1, ≥2 (original score: 0-3), component hepatitis activity 
in 0, ≥1 (original score: 0-3), and the total Nakanuma grade score in 0, 1, ≥2 (original 
score: 0-6). Ishak stage was reclassified in score 1-3 (original score : 0,1 = 1; 2,3 = 2; 
≥4 = 3). For the Nakanuma staging system the original scoring system was 
maintained. Ludwig staging system was scored 1-4 in which a Ludwig score of 0 was 
classified as score 1.  
Cox proportional hazard analysis was performed and associated hazard ratio 
(HR) was calculated for clinical, biochemical and histopathological variables. 
Exploratory analyses for correlations between liver biochemistry and histologic grade 
and stage to assess if liver biochemistry could reflect the degree of liver injury 
measured by liver histology, were performed by Spearman’s ranking test. 
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Statistical analyses were performed using SPSS version 20.0 software (SPSS, 
Inc., Chicago, IL). p<0.05 was considered statistically significant. 
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RESULTS 
 
Patient and biopsy characteristics 
Sixty-four patients were included, 40 male and 24 female, with a median follow-up of 
112 months (IQR 70-172). Patient characteristics, serum liver tests, and 
characteristic histologic features are summarized in table 1. Laboratory results are 
expressed in times upper limit of normal (xULN), as assays varied between hospitals 
and over time. Biopsies had a median length of 14 mm (IQR 11-19). The median 
number of portal tracts was 13 (IQR 9-19). Median disease duration at time of biopsy 
was 0 months (range 0-20). 
 
Distribution grade and stage 
Consensus on the evaluation of grade and stage was reached in 100% of cases.  
Grading: 
Ishak grading component interface hepatitis showed a median grade of 1 (range 1-2). 
Confluent necrosis was a relative infrequent finding in PSC liver biopsies with a 
median grade of 0 (range 0-1). The median grade of lobular inflammation and portal 
inflammation was 1 (range 0-2) and 1 (range 0-3), respectively. The majority of liver 
biopsies did not show Nakanuma grading components CA with a median of 0 (range 
0-3) nor HA, median 0 (range 0-2). Distribution of total Ishak and Nakanuma grade is 
shown in figure 1A,B.  
Staging:  
Figure 1C represents the Ishak stage, with a median of 2 (range 0-6). In figure 1D the 
Nakanuma stage (median 2 (range1-4)) is shown, derived from the components 
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fibrosis, bile duct loss and deposition of orcein positive granules score. Ludwig stage 
is displayed in figure 1E, showing a normal distribution  (mean 2, SD 1).  
  The distribution of Ishak and Nakanuma grading components, and the 
Nakanuma staging components is illustrated in figure 1 of the supplementary 
appendix. 
 
Patient outcome 
PSC related death, liver transplantation and cholangiocarcinoma 
Long-term follow up data were present for all patients. A total of 11 (17%) patients 
developed an endpoint; 3 patients were diagnosed with cholangiocarcinoma of whom 
2 patients died and eight patients underwent LTx. The median time to endpoint was 
86 months (IQR 43-142).  
Liver cirrhosis related symptoms: 
Data on the occurrence of CRS were available for 63 patients. A total of 16 (25%) 
patients developed CRS, of which nine developed more than one CRS. Nine (14%) 
patients developed varices, of whom one had a variceal bleeding. Ascites was found 
in six (10%) patients, splenomegaly in twelve (19%) and three (5%) patients 
presented with hepatic encephalopathy. The median time until presentation of the 
first CRS was 53 months (range 0-280), one patient presented with CRS at time of 
liver biopsy.  
 
Association of histologic grade and stage with patient outcome 
The prognostic significances of clinical, biochemical and histopathological 
parameters in predicting transplant-free survival, time to LTx and CRS, calculated by 
univariable Cox proportional hazard analyses are summarized in table 2.   
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Grading 
No significant association of the Ishak and Nakanuma grading systems and outcome 
measures transplant-free survival, time to LTx and CRS were shown.  
Staging 
A significant association was shown for Ishak staging system and transplant-free 
survival (p=0.04) as well as Ishak stage and time to LTx (p=0.005) (figure 2A,B). 
Univariable Cox proportional hazard analysis revealed a hazard ratio of 2.56; 95% CI 
1.11-5.89 (p=0.03) and HR 4.18; 95% CI 1.51-11.56 (p=0.006) for transplant-free 
survival and time to LTx, respectively (table 2). Nakanuma staging components 
fibrosis and CBP deposition were significantly associated with transplant-free survival 
and time to LTx, in which degree of CBP deposition was most pronounced (p <0.001 
vs p=0.005 respectively (supplementary appendix, table 3). This resulted in a strong 
significant association of Nakanuma staging system as a whole with both transplant-
free survival (p=<0.001) and time to LTx (p<0.001) (figure 2 C,D). The accompanying 
hazard ratio was 6.53; 95%CI 2.01-21.22 (p=0.002) and HR 7.05; 95% CI 1.77-28.11 
(p=0.006) for transplant-free survival and time to LTx, respectively. (table 2). The 
Ludwig staging system also showed a significant association with outcome 
measurements transplant-free survival and time to LTx (log-rank p=0.027 and 0.002, 
respectively), HR 1.94; 95% CI 1.00-3.79 (p=0.05) and HR 3.13; 95% CI 1.42-6.87 
(p= 0.005), respectively. (Figure 2 E,F; table 2) 
The endpoint cirrhosis related symptoms showed a significant association with 
the Ludwig staging system (log rank p=0.044). There was no association between 
the Nakanuma staging system as a whole and the development of CRS, though the 
Nakanuma staging component fibrosis did show a significant association (log rank 
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p=0.04). The Ishak staging system was not associated with the development of 
cirrhosis related symptoms (supplementary appendix, table 3). 
Univariable analyses of the other parameters showed that bilirubin and ALP 
were predictive factors for time to LTx. Though a trend for similar associations was 
seen for the endpoint transplant-free survival, this was not significant. However, MRS 
was a predictive factor for transplant-free survival. (table 2). 
An overview of median survival time per grade and stage, as well as the 
associations of histologic stage and grade with the three outcome measurements, 
calculated by log-rank test is given in the supplementary appendix, table 3.  
 
Correlation between histologic grade and stage and liver biochemistry values 
In table 3a and 3b correlation between liver biochemistry and histologic grade and 
stage are shown, calculated using Spearman’s rank correlation test. For some 
patients serum liver tests at time of liver biopsy were not  available. Liver 
biochemistry could be retrieved for AST n=56, ALT n= 51, ALP n=52, γGT n=46, total 
bilirubin n= 49.  
 
For grading, significant positive correlations between serum ALP level and the Ishak 
grading component portal inflammation (r=0.31, p=0.027), Ishak grading system as a 
whole (r=0.31, p=0.023) and the Nakanuma grading component HA (r=0.28, 
p=0.047) were shown. 
For staging, a positive correlation between total bilirubin level and Ishak 
staging system (r=0.32, p=0.027), as well as Nakanuma staging component fibrosis 
were demonstrated (r=0.29, p=0.042 ).  
Correlation coefficients did not exceed 0.33.    
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DISCUSSION 
With this study we have demonstrated that the Ishak, Nakanuma and Ludwig 
histological staging systems are predictive indicators of transplant-free survival and 
time to LTx in PSC.   
The Nakanuma staging system appeared to have the strongest predictive 
power, given its highest incremental hazard of long-term outcome corresponding to 
the stage progression. This may be explained by the fact that the Nakanuma staging 
system includes features that could be considered PSC appropriate. When focusing 
on the prognostic value of these individual components, degree of fibrosis and CBP 
deposition both predicted transplant-free survival and time to LTx, in which degree of 
CBP deposition was most discriminative (p <0.001, p=0.005 respectively). The 
Nakanuma staging component bile duct loss was not associated with outcome. This 
is in contrast with findings in PBC, where bile duct loss has been reported to be a 
predictor of disease progression.[25] Moreover, in PSC a peripheral liver biopsy 
might not be the best way to evaluate the extent of bile duct loss, since the disease 
affects the entire biliary tree and obliteration or obstruction of the larger central bile 
ducts may greatly affect progression to liver failure.[15] 
The prognostic value of the Ishak and Ludwig staging system, as well as 
Nakanuma component fibrosis implicate that degree of fibrosis is of important 
prognostic value in PSC. Similar findings have recently been demonstrated by Ruiz 
et al., who analyzed radiologic disease course in PSC by 3-dimensional MRC, and 
found that risk of progression was mainly dependent on the effects of biliary disease 
on liver parenchyma, rather than the effects of severe stricturing. [26]  
Necroinflammatory activity may predispose to development of CRS, however, 
no associations of histologic grading systems with CRS were shown. In PBC, 
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associations between histology and CRS seem to be more pronounced. Kakuda et 
al. showed a significant prognostic value of Nakanuma components fibrosis and CBP 
deposition, as well as Nakanuma and Ludwig staging systems as a whole for the 
development of cirrhosis related conditions before ursodeoxycholic acid (UDCA) 
treatment.[24] In a retrospective cohort of 58 PBC patients Chan et al. confirmed the 
Nakanuma system as a prognostic factor for liver related events, while the Ludwig 
system was not.[27] It must be stated that, despite that PSC and PBC are both 
cholangiopathies, sharing biochemical, clinical and a some morphological features, 
considerable differences exist in both disease entities[15]. The patchy distribution of 
affected bile ducts throughout the liver, with resulting sampling variability may be 
greater in PSC than in PBC.[19] Furthermore, the differences in statistical analyses 
as well as in definition of CRS between studies may contribute to these conflicting 
results. 
The extent to which histologic features, scored by the different scoring 
systems were present in PSC biopsies may indicate their applicability in PSC. The 
Nakanuma grading component cholangitis activity – though well recognized in PBC – 
is not typically seen in PSC. This was reflected in the presence of cholangitis activity 
in only 38% of cases in our cohort and the associated lack of predictive value. 
Hepatitis activity was detected in a minority of 27% of cases and had no predictive 
value. This may partly be explained by the exclusion of patients with auto-immune 
hepatitis overlap syndrome, in whom more severe hepatitis activity would be 
expected. PSC appropriate Nakanuma staging components bile duct loss and orcein 
positive granules were present in only 50% of cases. This could be due to the 
inclusion of biopsies taken at time of diagnosis, creating a cohort of patients with 
relatively early-stage disease.    
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Exploratory analyses for correlations between liver biochemistry and histologic 
grade and stage were performed to assess if liver biochemistry could reflect the 
degree of liver injury measured by liver histology. No strong correlations could be 
found, since correlation coefficients did not exceed 0.33. This suggests that liver 
biochemistry does not adequately reflect the degree of histologic injury. This finding 
is supported by a recent study of Queen et al. who evaluated the clinical course, 
endoscopic and pathologic findings of patients with normal liver biochemistry and 
showed that PSC patients can have cirrhosis and significant ductal disease, in the 
setting of normal liver biochemistry.[28]  
In 1995, Olsson et al. demonstrated a sampling variability of at least 20% for 
blind needle biopsy in PSC, which is often thought to refute its use as a prognostic 
measure.[29] The results of our study show that sampling variability is apparently not 
a major confounder. This is in line with results from a study by Angulo et al., who 
assessed the time course of histologic progression in PSC.[30] They observed 
progression in Ludwig stage in liver biopsies over two years’ time in 53% of PSC 
patients with an initial Ludwig stage of I-III.[30] In a Markov model they estimated that 
the risk of progression from Ludwig stage II to stage III of IV was 66% after two 
years. These results indicate that despite the issue of sampling variability, 
progression of liver disease can be evaluated using liver biopsy.[30] In addition, 
several clinical trials have included histologic change in grade-/stage as clinical 
endpoint.[7–13] Angulo et al. noted a significant improvement in the degree of portal 
inflammation – grade – after one year of budesonide treatment.[13] Degree of fibrosis 
and disease stage progressed despite treatment.[13] In a 2-year double-blind 
placebo-controlled study of high-dose UDCA, Mitchell et al. showed a significant 
reduction in progression of disease stage in the treatment group.[9] Fifty percent of 
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the placebo group showed no change in disease stage, while the other fifty percent 
showed progression by a single stage.[9] These studies indicate that both 
progression and improvement of liver disease grade-/stage can adequately be 
assessed by liver biopsy. [9,13,30] In addition, with the present study the prognostic 
value of liver biopsy on outcome was demonstrated. Therefore, liver histology 
appears to be a useful biomarker for progression, and its use as outcome measure in 
clinical trials deserves consideration. Moreover, for regulatory bodies, histology is still 
the gold standard as outcome parameter in many liver diseases. 
A limitation of this study is that multivariable Cox proportional hazard 
regression analysis, to analyze if  the prognostic value of the histology is independent 
of clinical and biochemical variables, could not be applied for methodological 
reasons. When performing a multivariable Cox proportional hazard regression 
analysis, the total numbers of events – not the total number of included cases – is 
important, to retain the validity of the outcome. [31] The most appropriate number of 
events per variable (EPV) to use in a multivariable analysis is 10. [32,33] For the 
present study a total of 140 events – an increase of the sample size up to 10 times – 
would be necessary to generate stable and interpretable results by multivariable 
analysis, which was unfortunately not feasible. 
The retrospective collection of serum liver tests and data on occurrence of liver 
CRS may be incomplete and hence may have led to a relative underestimation of the 
occurrence of liver CRS. However, follow-up data on solid clinical endpoints were 
complete in all 64 patients. Its retrospective character is also an asset in the sense 
that it yielded a median follow-up time of 112 months. Guido et al. described liver 
biopsy samples of 22 mm or more in length, with at least 11 portal tracks to be most 
reliable for grading and staging at least in the setting of viral hepatitis.[34] Although 
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the quality of liver biopsies of the present study was high with a median amount of 
portal tracks of 13 (IQR 9-19) and a median biopsy length of 14 mm (IQR 11-19), 
these optimal requirements were not met in all cases. The biopsies included in this 
study were all taken at time of diagnosis, which may result in spectrum bias. 
However, in figure 1. a normal distribution of grades and stages for most of the 
classification systems is shown, demonstrating that PSC patients diagnosed in both 
early and late disease stage were included in this study.  Lastly the percentage of 
small duct PSC in this study (16%) is relatively high in comparison with the 9% small 
duct PSC patients reported in a large population based epidemiology study.[18] 
Small duct PSC patients are known to have a better prognosis, which could influence 
results of outcome. For this reason analyses for associations between histological 
grading and staging and outcome were repeated in only the large duct patients of this 
cohort. Similar results were demonstrated (data not shown).  
In conclusion, applying the  Nakanuma, Ishak, and Ludwig histopathological 
staging systems in PSC is feasible and clinically relevant. Our results support the 
notion that histopathological scoring systems are likely candidates for surrogate 
endpoints and stratification in clinical trials in PSC, and may be used to assess 
noninvasive biomarkers for future trials. Validation of the applicability of these staging 
systems as well as determination of inter-observer variability to test the robustness of 
these scoring systems in PSC in a large multi-center cohort is warranted.  
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Figure legends 
Fig.1. Distribution of grading and staging systems. 
(A) Ishak grading system. (B) Nakanuma grading system. 
(C) Ishak staging system. (D) Nakanuma staging system. (E) Ludwig staging system. 
 
Fig. 2. Kaplan Meier survival curves. Endpoints transplant-free survival and time to 
liver transplantation,  shown for: (A,B) Ishak staging system. (C,D) Nakanuma 
staging system. (E,F) Ludwig staging system. 
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Table 1. Patient characteristics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SD = standard deviation; PSC = primary sclerosing cholangitis;  
IQR = inter quartile range; mm = millimeter; AST = aspartate  
aminotransferase; ALT = alanine aminotransferase; ALP = alkaline  
phosphatase; γGT = gamma-glutamyl transferase; xULN = times  
upper limit of normal; MRS = Mayo risk score 
* Data available for: AST n=56, ALT n= 51, ALP n=52, γGT n=46  
total bilirubin n= 49, MRS n=33. 
 
 
 
 
 
 
N 64 
Male [n (%)] 40          (63) 
Age follow-up (years) [mean (SD)] 49          (±15) 
Age at diagnosis PSC (years) [mean 
(SD)] 
38          (±14) 
Large duct PSC [n (%)]  54          (84) 
Inflammatory bowel disease [n (%)] 43          (67) 
     Ulcerative colitis [n (%)] 32          (50) 
     Crohn’s disease [n (%)] 8            (12) 
     Unspecified [n (%)] 3            (5) 
Portal tracts  [median (IQR)] 13          (9-19) 
Biopsy length (mm) [median (IQR)] 14          (11-19) 
Disease duration at time of biopsy 
(months) [median (range)] 
0            (0-20) 
Follow up time (months) [median 
(IQR)] 
112        (70-172) 
AST xULN [median (IQR)]* 1.40       (1.04-2.64) 
ALT xULN [median (IQR)]* 2.04       (1.40-4.43) 
ALP xULN [median (IQR)]* 1.65       (1.24-3.39) 
γGT xULN [median (IQR)]* 5.80       (3.02-11.10) 
Total bilirubin xULN [median (IQR)]* 0.82       (0.52-1.21) 
MRS* -0.28      (-0.77-0.78) 
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Table 2. Prognostic significances of clinical, biochemical and histopathological parameters in 
predicting transplant-free survival, time to LTx and cirrhosis related symptoms, calculated by 
univariable Cox proportional hazard analyses.  
 
 
Transplant-free 
survival 
HR    (95% CI) 
 
               
p-value 
Time to LTx 
                               
HR    (95% CI) 
 
               
p-value 
Cirrhosis related 
symptoms* 
HR    (95% CI) 
 
              
p-value 
Sex 0.97 (0.28 – 3.32) 0.96 0.57 (0.12-2.85) 0.50 0.37 (0.11-1.30) 0.12 
Age at PSC 
diagnosis 
1.01 (0.96 – 1.05) 0.63 1.00 (0.95-1.05) 0.97 1.01 (0.97-1.04) 0.70 
PSC type 0.67 (0.09-5.28) 0.71 0.04 (0.00-301.42) 0.48 0.37 (0.05-2.78) 0.33 
Coexisting IBD 0.43 (0.13-1.43) 0.17 0.66 (0.16-2.77) 0.57 1.95 (0.56-6.84) 0.30 
Cirrhosis related 
symptoms* 
1.19 (0.31-4.62) 0.80 2.07 (0.46–9.25) 0.34 NA NA 
AST* 1.18 (1.00-1.40) 0.05 1.11 (0.87-1.43) 0.41 1.07 (0.91-1.26) 0.42 
ALT* 1.05 (0.91-1.21) 0.53 1.02 (0.84-1.24) 0.86 1.07 (0.97-1.19 0.18 
ALP* 1.27 (0.96-1.68) 0.10 1.41 (1.03-1.93) 0.03 1.02 (0.77-1.34) 0.90 
γGT* 0.95 (0.82-1.10) 0.51 0.98 (0.84-1.14) 0.78 1.05 (0.97-1.14) 0.20 
Total bilirubin* 1.53 (0.99-2.35) 0.05 1.73 (1.07 – 2.79) 0.03  1.17 (0.80-1.70) 0.42 
MRS* 3.41 (1.15-10.09 0.03 3.19 (0.97-10.47) 0.06 1.31 (0.72-2.38) 0.38 
Ishak grade 
(1-4) 
1.50 (0.86-2.61) 0.15 1.56 (0.82-2.99) 0.18 1.11 (0.69-1.79) 0.68 
Nakanuma 
grade (0, 1, ≥2) 
1.35 (0.65-2.82) 0.43 1.42 (0.60-3.31) 0.43 1.26 (0.69-2.30) 0.45 
Ishak stage  
1-3) 
2.56 (1.11-5.89) 0.03 4.18 (1.51-11.56) 0.006 1.09 (0.95-3.81) 0.07 
Nakanuma 
stage (1-4)* 
6.53 (2.01-21.22) 0.002 7.05 (1.77-28.11) 0.006 1.57 (0.70-3.51) 0.28 
Ludwig stage 
(1-4) 
1.94 (1.00-3.79) 0.05 3.13 (1.42-6.87) 0.005 1.16 (0.66-2.00) 0.62 
HR = Hazard Ratio; CI = confidence interval; LTx = liver transplantation; PSC = primary sclerosing cholangitis; 
IBD = inflammatory bowel disease;  AST = aspartate aminotransferase; ALT = alanine aminotransferase; ALP 
= alkaline phosphatase; γGT = gamma-glutamyl transferase; MRS = Mayo risk score; NA = not assessed. 
* Data available for: AST n=56, ALT n= 51, ALP n=52, γGT n=46, total bilirubin n= 49, MRS n=33, Nakanuma 
stage n=58; cirrhosis related symptoms n=63. 
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Table 3a. Correlation between grading and liver biochemistry values. 
 
 Interface 
activity  
(0, 1, ≥2)  
Confluent 
necrosis 
(0, ≥1) 
Lobular 
inflammation 
(0, 1, ≥2)  
Portal 
inflammation 
(0, 1, ≥2)  
Ishak total 
(1-4) 
CA 
(0, 1, ≥2) 
HA 
(0, ≥1) 
Nakanuma  
total 
(0, 1, ≥2)  
AST* 
 
0.062 
p=0.650 
-0.018 
p=0.896 
0.094 
p=0.490 
0.066 
p=0.627 
0.171 
p=0.207 
-0.038 
p=0.783 
0.236 
p=0.080 
0.100 
p=0.462 
ALT* 
 
-0.122 
p=0.393 
-0.041 
p=0.774 
0.055 
p=0.704 
-0.025 
p=0.863 
-0.009 
p=0.951 
-0.201 
p=0.158 
0.052 
p=0.716 
-0.146 
p=0.307 
ALP* 
 
0.256 
p=0.067 
-0.247 
p=0.078 
0.163 
p=0.248 
0.306 
p=0.027 
0.314 
p=0.023 
0.143 
p=0.311 
0.277 
p=0.047 
-0.132 
p=0.360 
γGT* 
 
0.146 
p=0.333 
0.062 
p= 0.683 
-0.093 
p=0.540 
0.001 
p=0.996 
0.115 
p=0.446 
-0.018 
p=0.905 
0.239 
p=0.110 
0.126 
p=0.402 
Total* 
bilirubin 
0.141 
p=0.334 
-0.011 
p=0.940 
-0.072 
p=0.621 
0.268 
p=0.063 
0.254 
p=0.090 
-0.241 
p=0.095 
0.093 
p=0.526 
-0.050 
p=0.731 
CA = cholangitis activity; HA = hepatitis activity; AST = aspartate aminotransferase; ALT = alanine 
aminotransferase; ALP = alkaline phosphatase; γGT = gamma-glutamyl transferase.  
* Data available for: AST n=56, ALT n= 51, ALP n=52, γGT n=46, total bilirubin n= 49.  
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Table 3b. Correlation between staging and liver biochemistry value, calculated by Spearman’s 
rank correlation test. 
 
 Ishak 
(1-3) 
Fibrosis 
(0-3) 
Bile duct loss 
(0-3) 
Orcein positive 
granules**  
(0-3) 
Nakanuma 
total** 
(1-4) 
Ludwig 
(1-4) 
AST* 
 
0.050 
p=0.717 
-0.028 
p=0.840 
0.039 
p=0.778 
-0.028 
p=0.843 
0.074 
p=0.606 
-0.011 
p=0.938 
ALT* 
 
-0.167 
p=0.241 
-0.191 
p=0.179 
-0.040 
p=0.780 
-0.109 
p=0.465 
-0.085 
p=0.569 
-0.162 
p=0.256 
ALP* 
 
0.180 
p=0.201 
0.088 
p=0.535 
0.001 
p=0.992 
0.024 
p=0.870 
0.146 
p=0.322 
0.131 
p=0.356 
γGT* 
 
0.096 
p=0.528 
0.049 
p=0.748 
0.110 
p=0.468 
0.188 
p=0.233 
0.114 
p=0.473 
0.045 
p=0.769 
Total* 
bilirubin 
0.317 
p=0.027 
0.292 
p=0.042 
0.245 
p=0.090 
0.121 
p=0.429 
0.255 
p=0.091 
0.090 
p=0.537 
AST = aspartate aminotransferase; ALT = alanine aminotransferase; ALP = alkaline phosphatase;  
γGT = gamma glutamyl transferase.  
*  Data available for: AST n=56, ALT n= 51, ALP n=52,  γGT n=46, total bilirubin n= 49. 
** Data available for: n=58. 
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